J Korean Med Assoc.  2016 Feb;59(2):108-113. 10.5124/jkma.2016.59.2.108.

The role of pathologists in multidisciplinary cancer care

• Lee KS
• Choe G

• KMID: 2153715
• DOI: http://doi.org/10.5124/jkma.2016.59.2.108

Abstract

In recent years there has been significant growth in multidisciplinary cancer treatment. In cancer patient management, multidisciplinary cancer treatment is essential for evaluation of treatment response and proper decision making. Multidisciplinary cancer treatment has some systematic problems in Korea; however, it is expected to be increasingly activated in tertiary medical institutions. Pathologists are core members of multidisciplinary cancer treatment teams. We reviewed the pathologist's role in multidisciplinary cancer treatment. The days of precision medicine have arrived with remarkable development in molecular pathology. Pathologists not only histologically confirm the cancer diagnosis and pathologic stage but also evaluate both prognostic factors and predictive factors determining targeted therapy. Pathologists' participation in multidisciplinary cancer treatment and explanation of pathologic results can draw good curative effect and improve patient satisfaction. The only caveat is that pathologists need to be brought down to the patient's level while describing pathologic findings. We suspect that pathologists' role will expand as pathologists participate in multidisciplinary cancer treatment in the era of precision medicine.

Keyword

Multidisciplinary cancer care; Pathologist; Precision medicine

MeSH Terms

Decision Making
Diagnosis
Humans
Korea
Pathology, Molecular
Patient Satisfaction

Reference

1. Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012; 344:e2718.

2. Kane B, Luz S, O'Briain DS, McDermott McDermott. Multidisciplinary team meetings and their impact on workflow in radiology and pathology departments. BMC Med. 2007; 5:15.

3. Stricker T, Catenacci DV, Seiwert TY. Molecular profiling of cancer: the future of personalized cancer medicine. A primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol. 2011; 38:173–185.

4. Pasche B, Grant SC. Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. JAMA. 2014; 311:1975–1976.

5. Osuna D, de Alava E. Molecular pathology of sarcomas. Rev Recent Clin Trials. 2009; 4:12–26.

6. Oxley J. Reviewing negative prostatic core biopsies for the multidisciplinary team meeting. Histopathology. 2005; 47:643–644.

7. Jacobson JO. Multidisciplinary cancer management: a sys-tems-based approach to deliver complex care. J Oncol Pract. 2010; 6:274–275.

8. Lee KS, Kwak Y, Nam KH, Kim DW, Kang SB, Choe G, Kim WH, Lee HS. c-MYC copy-number gain is an independent prognostic factor in patients with colorectal cancer. PLoS One. 2015; 10:e0139727.

9. Pruthi S, Brandt KR, Degnim AC, Goetz MP, Perez EA, Reynolds CA, Schomberg PJ, Dy GK, Ingle JN. A multidis-ciplinary approach to the management of breast cancer, part 1: prevention and diagnosis. Mayo Clin Proc. 2007; 82:999–1012.

10. Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, Zhang W, Grogan TM, Lee CT, Jheon S, Chung JH. Detection of ALK gene rearrangement in non-small cell lung cancer: a compa-rison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011; 6:1359–1366.

11. Slodkowska J, Rojo MG. Digital pathology in personalized cancer therapy. Folia Histochem Cytobiol. 2011; 49:570–578.